Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report
<h2>Clinical Practice Points</h2> <ul><li>•Tarlatamab's onset of tumor regression can be as short as 2 weeks.</li><li>•Rechallenging tarlatamab after grade 3 CRS with standard premedication is safe.</li><li>•Tarlatamab combined with IMRT offers safe and highly effective CNS control.</li><li>•A collapsed lung from tumor burden may re-expand with tarlatamab monotherapy.</li></ul>
Authors
- Chao Huang (ORCID: https://orcid.org/0000-0003-4215-3630)
- Haoran Li (ORCID: https://orcid.org/0009-0005-2375-9188)
- Jun Zhang (ORCID: https://orcid.org/0000-0001-7886-6187)
- Prakash Raj Neupane
- Timothy Schieber
Institutions
- The University of Kansas Cancer Center (US)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1016/j.cllc.2024.12.005
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85